Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNOS radioligand
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
An iNOS radioligand is a radiolabeled imaging agent designed to target inducible nitric oxide synthase (iNOS), an enzyme upregulated during microglial activation and neuroinflammation. These radioligands are developed for use in positron emission tomography (PET) or single-photon emission tomography (SPECT) imaging to noninvasively monitor oxidative stress and neuroinflammatory dynamics. In preclinical models of Parkinson's disease, iNOS-targeting radioligands have demonstrated a strong association with alpha-synuclein pathology and microglial density, offering a promising alternative to traditional neuroinflammation targets like TSPO.
- Other names
- iNOS PET traceriNOS imaging agentiNOS tracer
02
Targets
NOS3 (eNOS)NOS2 (Nitric Oxide Synthase 2)NOS1 (nNOS)
Beyond the preview
Go deeper on iNOS radioligand.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNOS radioligand.